Compare American Homes 4 Rent Class A (AMH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Homes 4 Rent Class A vs Recursion Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Recursion Pharmaceuticals Inc trades at $3.52 (market cap $1.89B). The key difference: American Homes 4 Rent Class A is far larger — about 6.3× Recursion Pharmaceuticals Inc's market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMH | RXRX | |
|---|---|---|
Market Cap | $11.97B | $1.89B |
Sector | Real Estate | Health |
52-Week High | $36.74 | $6.79 |
52-Week Low | $27.38 | $2.84 |
Enterprise Value | $17.05B | $1.31B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
